DuoGenic StemCells corporation (7607.TWO)
TWD 24.2
(1.68%)
TWD 24.2
(1.68%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 13.66 Million | 6.86 Million | 2.29 Million |
| Cost of Revenue | 8.76 Million | 7.31 Million | 7.27 Million |
| Gross Profit | 4.89 Million | -452 Thousand | -4.97 Million |
| Operating Expenses | 4.89 Million | 32.96 Million | 18.16 Million |
| Selling, General and Administrative Expenses | 35.47 Million | 19.22 Million | 7.86 Million |
| Research and Development Expenses | 14.3 Million | 13.74 Million | 10.3 Million |
| Other Expenses | - | -301 Thousand | 334 Thousand |
| Cost and Expenses | 58.55 Million | 40.28 Million | 25.43 Million |
| Operating Income | -44.88 Million | -33.42 Million | -23.14 Million |
| Interest Expense | 160 Thousand | 68 Thousand | 47 Thousand |
| Income Tax Expense | 167 Thousand | 316 Thousand | -865 Thousand |
| Earnings before Tax | -45.06 Million | -33.73 Million | -22.84 Million |
| Net Income | -45.23 Million | -34.05 Million | -21.98 Million |
| Earnings Per Share Basic | -1.50 | -1.18 | -0.86 |
| Earnings Per Share Diluted | -1.50 | -1.18 | -0.86 |
| Weighted Average Shares Outstanding | 30.24 Million | 28.79 Million | 25.6 Million |
| Weighted Average Shares Outstanding (Diluted) | 30.24 Million | 28.79 Million | 25.6 Million |
| Gross Margin | 0.36 | -0.07 | -2.17 |
| EBIT Margin | -2.77 | -4.09 | -8.92 |
| Profit Margin | -3.31 | -4.96 | -9.57 |
| EBITDA | -37.89 Million | -28.33 Million | -20.13 Million |
| Earnings Before Tax Margin | -3.28 | -4.87 | -10.07 |
| Breakdown | 2024 Q2 | 2023 FY | 2023 Q4 | 2023 Q2 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Revenue | 5.09 Million | 13.66 Million | 6.36 Million | 7.3 Million | 6.86 Million | 4.57 Million |
| Cost of Revenue | 6.74 Million | 12.53 Million | 6.07 Million | 6.45 Million | 7.31 Million | 4.22 Million |
| Gross Profit | -1.65 Million | 1.13 Million | 288 Thousand | 848 Thousand | -452 Thousand | 345 Thousand |
| Operating Expenses | 31.09 Million | 46.02 Million | 23.32 Million | 22.69 Million | 32.96 Million | 20.14 Million |
| Selling, General and Administrative Expenses | 15.84 Million | - | 15.67 Million | 16.03 Million | - | 12.21 Million |
| Research and Development Expenses | 15.24 Million | - | 7.64 Million | 6.66 Million | - | 7.92 Million |
| Other Expenses | - | -288 Thousand | - | - | -301 Thousand | - |
| Cost and Expenses | 37.83 Million | 58.55 Million | 29.39 Million | 29.15 Million | 40.28 Million | 24.36 Million |
| Operating Income | -32.74 Million | -44.88 Million | -23.03 Million | -21.84 Million | -33.42 Million | -19.79 Million |
| Interest Expense | 112 Thousand | 160 Thousand | 110 Thousand | 50 Thousand | 68 Thousand | 41 Thousand |
| Income Tax Expense | -1.13 Million | 167 Thousand | 372 Thousand | -205 Thousand | 316 Thousand | 316 Thousand |
| Earnings before Tax | -33.43 Million | -45.06 Million | -22.89 Million | -22.17 Million | -33.73 Million | -19.28 Million |
| Net Income | -32.29 Million | -45.23 Million | -23.26 Million | -21.96 Million | -34.05 Million | -19.59 Million |
| Earnings Per Share Basic | -1.06 | - | -0.76 | -0.73 | - | -0.66 |
| Earnings Per Share Diluted | -1.06 | - | -0.76 | -0.73 | - | -0.66 |
| Weighted Average Shares Outstanding | 30.55 Million | 30.24 Million | 30.54 Million | 29.92 Million | 28.79 Million | 29.69 Million |
| Weighted Average Shares Outstanding (Diluted) | 30.55 Million | 30.24 Million | 30.54 Million | 29.92 Million | 28.79 Million | 29.69 Million |
| Gross Margin | -0.32 | 0.08 | 0.05 | 0.12 | -0.07 | 0.08 |
| EBIT Margin | -5.71 | - | -3.06 | -2.52 | - | -3.65 |
| Profit Margin | -6.34 | -3.31 | -3.66 | -3.01 | -4.96 | -4.29 |
| EBITDA | -29.09 Million | - | -19.44 Million | -18.42 Million | - | -16.67 Million |
| Earnings Before Tax Margin | -6.43 | -3.28 | -3.62 | -2.99 | -4.87 | -4.33 |
MC
GRAT
SVT
UGP
MSP
6794